title: Coffee consumption, genetic susceptibility and bladder cancer risk.
abstract: OBJECTIVE
  We evaluated the bladder cancer risk associated with coffee consumption in a case-control study in Spain and examined the gene-environment interactions for genetic variants of caffeine-metabolizing enzymes.
  
  
  METHODS
  The analyses included 1,136 incident cases with urothelial carcinoma of the urinary bladder and 1,138 controls. Odds ratios (OR) and 95% confidence intervals (CI) were adjusted for area, age, gender, amount of cigarette smoking, and years since quitting among former smokers.
  
  
  RESULTS
  The OR (95% CI) for ever consumed coffee was 1.25 (0.95-1.64). For consumers of 1, 2, 3, and 4 or more cups/day relative to never drinkers, OR were, respectively, 1.24 (0.92-1.66), 1.11 (95% CI 0.82-1.51), 1.57 (1.13-2.19), and 1.27 (0.88-1.81). Coffee consumption was higher in smokers compared to never smokers. The OR for drinking at least 4 cups/day was 1.13 (0.61-2.09) in current smokers, 1.57 (0.86-2.90) in former smokers, and 1.23 (0.55-2.76) in never smokers. Gene-coffee interactions evaluated in NAT2, CYP1A2, and CYP2E1-02 and CYP1A1 were not identified after adjusting for multiple testing.
  
  
  CONCLUSIONS
  We observed a modest increased bladder cancer risk among coffee drinkers that may, in part, be explained by residual confounding by smoking. The findings from the gene-coffee interactions need replication in further studies.
authors.affiliation: Centre for Research in Environmental Epidemiology (CREAL), PRBB Building, Doctor Aiguader, 88, 08003, Barcelona, Spain. cvillanueva@creal.cat
authors.forename: Cristina M
authors.initials: CM
authors.lastname: Villanueva
authors.forename: Debra T
authors.initials: DT
authors.lastname: Silverman
authors.forename: Cristiane
authors.initials: C
authors.lastname: Murta-Nascimento
authors.forename: Núria
authors.initials: N
authors.lastname: Malats
authors.forename: Montserrat
authors.initials: M
authors.lastname: Garcia-Closas
authors.forename: Francesc
authors.initials: F
authors.lastname: Castro
authors.forename: Adonina
authors.initials: A
authors.lastname: Tardon
authors.forename: Reina
authors.initials: R
authors.lastname: Garcia-Closas
authors.forename: Consol
authors.initials: C
authors.lastname: Serra
authors.forename: Alfredo
authors.initials: A
authors.lastname: Carrato
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Rothman
authors.forename: Francisco X
authors.initials: FX
authors.lastname: Real
authors.forename: Mustafa
authors.initials: M
authors.lastname: Dosemeci
authors.forename: Manolis
authors.initials: M
authors.lastname: Kogevinas
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001191:Arylamine N-Acetyltransferase / Q000235:genetics; D016022:Case-Control Studies; D003069:Coffee / Q000633:toxicity*; D016001:Confidence Intervals; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012307:Risk Factors; D013030:Spain; D001749:Urinary Bladder Neoplasms / Q000453:epidemiology* / Q000235:genetics*
chemical_list: D003069:Coffee; C504573:CYP1A2 protein, human; D019363:Cytochrome P-450 CYP1A1; D019388:Cytochrome P-450 CYP1A2; D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human
references.citation: Pharmacogenetics. 1992 Apr;2(2):73-7
references.pmid: 1302044
references.citation: Gen Pharmacol. 1996 Mar;27(2):245-9
references.pmid: 8919637
references.citation: Biochem Pharmacol. 1994 May 18;47(10):1767-76
references.pmid: 8204093
references.citation: Eur J Epidemiol. 1997 Oct;13(7):795-800
references.pmid: 9384269
references.citation: Eur J Epidemiol. 2008;23(5):355-62
references.pmid: 18365755
references.citation: Cancer Epidemiol Biomarkers Prev. 1996 Mar;5(3):161-6
references.pmid: 8833615
references.citation: Int J Urol. 2004 Jan;11(1):11-9
references.pmid: 14678179
references.citation: Eur J Cancer Prev. 2002 Apr;11(2):137-45
references.pmid: 11984131
references.citation: N Engl J Med. 1999 May 6;340(18):1390-7
references.pmid: 10228189
references.citation: Int J Cancer. 2001 Sep;93(6):880-7
references.pmid: 11519052
references.citation: PLoS Genet. 2007 Feb 23;3(2):e29
references.pmid: 17319747
references.citation: Cancer Causes Control. 2000 Dec;11(10):925-31
references.pmid: 11142527
references.citation: Lancet. 2005 Aug 20-26;366(9486):649-59
references.pmid: 16112301
references.citation: Ann Epidemiol. 1993 Nov;3(6):586-91
references.pmid: 7921304
references.citation: Eur J Cancer Prev. 2007 Oct;16(5):385-9
references.pmid: 17923807
references.citation: Cancer Causes Control. 2001 Apr;12(3):231-8
references.pmid: 11405328
references.citation: Int J Cancer. 2006 Apr 15;118(8):2040-7
references.pmid: 16284957